Grundlæggende statistik
| LEI | 54930025OZD2GGSQ7L42 |
| CIK | 1764791 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Orphazyme A/S - ADR
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| February 10, 2023 |
ORPH / Orphazyme A/S / LSP V Cooperatieve U.A. - SC 13G/A Passive Investment SC 13G/A 1 d398480dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Orphazyme A/S (Name of Issuer) Ordinary Shares (Title of Cla |
|
| September 26, 2022 |
Exhibit 99.2 Company announcement Orphazyme A/S No. 36/2022 c/o COBIS A/S, Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme reports financial results in Interim Report First Half 2022 Copenhagen, Denmark, September 26, 2022 ? Orphazyme A/S (ORPHA.CO) (the ?Company?) today announces its Interim Report First Half 2021 for the period January 1 ? Jun |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive of |
|
| September 26, 2022 |
Interim Report First Half 2022 Exhibit 99.1 Company announcement No. 36/2022 Orphazyme A/S Ole Maal?es Vej 3 DK-2200 Copenhagen N CVR No.: 32266355 Interim Report First Half 2022 Copenhagen, Denmark, September 26, 2022 ? Orphazyme A/S (ORPHA.CO) (the ?Company?), today announces its Interim Report First Half 2022 for the period January 1 ? June 30, 2022. Anders Vadsholt, Chief Executive Officer and Chief Financial Officer said, |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| June 29, 2022 |
Resolutions passed at the Annual General Meeting Exhibit 99.1 Company announcement Orphazyme A/S No. 33/2022 Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Resolutions passed at the Annual General Meeting Copenhagen, Denmark, June 29, 2022 ? Orphazyme A/S (ORPHA.CO) (the ?Company?), today held its Annual General Meeting, at which the Annual General Meeting: Financial year 2021 and 2022 ? Took note of t |
|
| June 28, 2022 |
Orphazyme A/S –Long-Term Incentive Program 2021 – Danish and Swiss Participants. Exhibit 4.4 21 April 2021 | Danish and Swiss participants Orphazyme A/S ? Long-Term Incentive Programme General Terms and Conditions for Restricted Share Units and Performance Share Units Page: 2 of 11 Content 1 Introduction 3 2 Restricted Share Units (RSUs) 4 3 Performance Share Units (PSUs) 6 4 Cash settlement 8 5 Claw back 8 6 Adjustments in case of changes to the Company?s capital structure 8 |
|
| June 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| June 28, 2022 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Anders Fink Vadsholt, certify that: 1. I have reviewed this annual report on Form 20-F of Orphazyme A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state |
|
| June 28, 2022 |
Orphazyme A/S – Code of Business Conduct and Ethics. Exhibit 14.1 Code of business conduct and ethics Introduction Purpose and Scope The Board of Directors of Orphazyme A/S (together with its subsidiaries as existing from time- to-time, ?Orphazyme?) have established this Code of Business Conduct and Ethics (the ?Code?) to aid Orphazyme?s directors, officers and employees in making ethical and legal decisions when conducting Orphazyme?s business and |
|
| June 28, 2022 |
Articles of Association of Orphazyme A/S, as amended February 15, 2022 Exhibit 1.1 Articles of Association Orphazyme A/S, CVR no. 32 26 63 55 Page: 2 of 11 1 Name and objects 1.1 The Company’s name is Orphazyme A/S. 1.2 The Company’s objects are research, development, production, marketing, sales and/or licensing of medicinal products for treatment of various disorders, including lysosomal storage diseases (LSD), neuromuscular disorders and other related diseases, as |
|
| June 28, 2022 |
Exhibit 4.1 Asset Purchase Agreement regarding certain assets in Orphazyme A/S in restructuring Page-2 This Asset Purchase Agreement (the "Agreement") is on this day entered into between: Seller: Orphazyme A/S in restructuring, CVR no. 32 26 63 55, a company incorporated and registered under the laws of Denmark having its registered address at Ole Maal?es Vej 3, 2200 K?benhavn, Denmark (the "Selle |
|
| June 28, 2022 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended December 31, 2021 (the ?Report?) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the ?E |
|
| June 28, 2022 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Anders Fink Vadsholt, certify that: 1. I have reviewed this annual report on Form 20-F of Orphazyme A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state |
|
| June 28, 2022 |
Orphazyme A/S – Board Incentive Program 2021. Exhibit 4.6 Orphazyme A/S ? Share-based incentive program for the Board of Directors for 2021 General Terms and Conditions Page: 2 of 9 Contents 1 Introduction 3 2 Grant of Restricted Share Units 3 3 Vesting of Restricted Share Units 4 4 Exercise of Restricted Share Units 4 5 Lapse of Restricted Share Units 5 6 Cash settlement 5 7 Claw back 5 8 Adjustments in case of changes to the Company?s capit |
|
| June 28, 2022 |
Description of Share Capital and Articles of Association Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION Securities registered under Section 12(b) of the Securities Exchange Act of 1934 (the ?Exchange Act?), as of December 31, 2021: Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, nominal value DKK 1 per share ORPH The Nasdaq Global Sele |
|
| June 28, 2022 |
Orphazyme A/S - Long-Term Incentive Program 2021 – U.S. Participants. Exhibit 4.3 21 April 2021 | U.S. participants Orphazyme A/S ? Long-Term Incentive Programme General Terms and Conditions for Restricted Share Units and Performance Share Units Page: 2 of 14 Contents 1 Introduction 3 2 Restricted Share Units (RSUs) 4 3 Performance Share Units (PSUs) 6 4 Cash settlement 9 5 Claw back 9 6 Adjustments in case of changes to the Company?s capital structure 9 7 Takeover |
|
| June 28, 2022 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended December 31, 2021 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “E |
|
| June 21, 2022 |
Exhibit 99.1 Company announcement Orphazyme A/S No. 32/2022 Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Updated notice to holders of ADSs regarding termination of Deposit Agreement NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (?ADSs?) EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS (?ADRs?) REPRESENTING DEPOSITED COMMON SHARES OF: ORPHAZYME A/S ONE ADS R |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| June 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| June 9, 2022 |
Notice to convene Annual General Meeting Exhibit 99.3 Company announcement No. 31/2022 Orphazyme A/S Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Notice to convene Annual General Meeting Copenhagen, Denmark, June 7, 2022 ? Orphazyme A/S (ORPHA.CO) (the ?Company?), today announces the notice to convene the Company?s Annual General Meeting to be held on: Wednesday, June 29, 2022, at 2:00 PM (CE |
|
| June 9, 2022 |
Table of Contents Exhibit 99.2 ANNUAL REPORT 2021 Orphazyme A/S Company registration no.: 32266355 Ole Maal?es Vej 3, DK-2200 Copenhagen N, Denmark Table of Contents Contents Introduction 3 Management Report 5 2021 Financial Review 7 Outlook 8 Shareholder Information 9 Corporate Governance 11 Risk Management 15 Corporate Social Responsibility 17 Board of Directors and Executive Management 22 Corpo |
|
| June 9, 2022 |
Orphazyme Announces Publication of 2021 Financial Results and Annual Report Exhibit 99.1 Company announcement No. 30/2022 Annual report Orphazyme A/S Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme Announces Publication of 2021 Financial Results and Annual Report Copenhagen, Denmark, June 7, 2022 ? Orphazyme A/S (ORPHA.CO) (?Orphazyme? or the ?Company?), today reports its financial results for the period from January 1, |
|
| May 31, 2022 |
Orphazyme completes sale of substantially all of its assets and business activities to KemPharm Exhibit 99.2 Company announcement No. 29/2022 Inside information Orphazyme A/S Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme completes sale of substantially all of its assets and business activities to KemPharm Copenhagen, Denmark, May 31, 2022 ? With reference to company announcement no. 24/2022 dated May 15, 2022, regarding the signing of an |
|
| May 31, 2022 |
Restructuring proposal adopted by creditors Exhibit 99.1 Company announcement Orphazyme A/S in restructuring No. 28/2022 Ole Maal?es Vej 3 Inside information DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Restructuring proposal adopted by creditors Copenhagen, Denmark, May 30, 2022 ? Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company, announces tha |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| May 23, 2022 |
Changes to the Board of Directors Exhibit 99.1 Company announcement Orphazyme A/S in restructuring No. 27/2022 Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Changes to the Board of Directors Copenhagen, Denmark, May 23, 2022 ? Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company, has previously announced its entry into an |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| May 18, 2022 |
Exhibit 99.1 Company announcement Orphazyme A/S in restructuring No. 26/2022 Ole Maal?es Vej 3 Inside information DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Restructuring Proposal Copenhagen, Denmark, May 18, 2022 ? Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company, announces that the enclosed restru |
|
| May 16, 2022 |
Updated Financial Calendar for 2022 Company announcement Orphazyme A/S in restructuring No. 25/2022 Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Updated Financial Calendar for 2022 Copenhagen, Denmark, May 16, 2022 ? Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company, announces an update to the Company?s financial calend |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| May 16, 2022 |
SEC FILE NUMBER 001-39545 CUSIP NUMBER 687305102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 16, 2022 |
Exhibit 99.1 Company announcement Orphazyme A/S in restructuring No. 24/2022 Ole Maal?es Vej 3 Inside information DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc. Copenhagen, Denmark, 15 May 2022 ? KemPharm to acquire Orphazyme assets, including those |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| May 2, 2022 |
SEC FILE NUMBER 001-39545 CUSIP NUMBER 687305102 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 29, 2022 |
Orphazyme announces update on in-court restructuring proceedings Exhibit 99.1 Orphazyme A/S in restructuring Company announcement No. 23/2022 Inside information www.orphazyme.com Company Registration No. 32266355 Orphazyme announces update on in-court restructuring proceedings Copenhagen, Denmark, April 29, 2022 ? Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company, announces an update to the in |
|
| April 29, 2022 |
Updated Financial Calendar for 2022 Exhibit 99.1 Orphazyme A/S in restructuring Company announcement No. 22/2022 www.orphazyme.com Company Registration No. 32266355 Updated Financial Calendar for 2022 Copenhagen, Denmark, April 28, 2022 ? Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company, announces an update to the Company?s Financial Calendar for the remainder of |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39545 Orphazyme A/S in restructuring (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39545 Orphazyme A/S in restructuring (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39545 Orphazyme A/S in restructuring (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal |
|
| April 7, 2022 |
Statutory restructuring plan adopted by creditors Exhibit 99.1 Orphazyme A/S in restructuring Company announcement No. 20/2022 Inside information Ole Maal?es Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Statutory restructuring plan adopted by creditors Copenhagen, Denmark, April 7, 2022 ? Orphazyme A/S in restructuring (ORPHA.CO) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company, announces t |
|
| April 6, 2022 |
Updated Financial Calendar for 2022 Exhibit 99.1 Orphazyme A/S in restructuring Company announcement No. 19/2022 Ole Maal?es Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Updated Financial Calendar for 2022 Copenhagen, Denmark, April 6, 2022 ? Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company, announces an update to the Company?s F |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39545 Orphazyme A/S in restructuring (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal |
|
| April 6, 2022 |
Exhibit 99.1 Orphazyme A/S in restructuring Company announcement No. 18/2022 Ole Maal?es Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Notice received from the Depositary to holders of ADSs regarding termination of Deposit Agreement NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (?ADSs?) EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS (?ADRs?) REPRESENTING DEPOSITED CO |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| April 4, 2022 |
Correction: Proposal for a statutory restructuring plan Exhibit 99.1 Orphazyme A/S in restructuring Company announcement No. 17/2022 Inside information Ole Maal?es Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Correction: Proposal for a statutory restructuring plan Copenhagen, Denmark, April 4, 2022 ? Orphazyme A/S in restructuring (ORPHA.CO) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company, today |
|
| April 4, 2022 |
Exhibit 99.2 Forel?big modregnet balance for Orphazyme A/S under rekonstruktion pr. 11. marts 2022/Interim set-off balance of Orphazyme A/S in reconstruction 11 March 2022 Bel?b i tusind DKK / Thousand DKK Rekonstruktion/reconstruction Konkurs/bankruptcy Bogf?rt v?rdi/ booked value Reguler-inger/ adjust-ments Vurdering/ Valuation Virksom-heds pant /Pledge floating charge Netto-aktiver/ net assets |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| April 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| April 1, 2022 |
Voluntary delisting of ADSs has become effective EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S in restructuring Company announcement No. 16/2022 Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Voluntary delisting of ADSs has become effective Copenhagen, Denmark, March 31, 2022 – Orphazyme A/S in restructuring (ORPHA.CO) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical compa |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 31, 2022 |
Proposal for a statutory restructuring plan Exhibit 99.1 Orphazyme A/S in restructuring Company announcement No. 15/2022 Inside information Ole Maal?es Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Proposal for a statutory restructuring plan Copenhagen, Denmark, March 31, 2022 ? Orphazyme A/S in restructuring (ORPHA.CO) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company, announces that t |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. 001-39545 (Commission File Number) Orphazyme A/S in restructuring (Exact name of registrant as spec |
|
| March 31, 2022 |
EX-99.2 3 orph-ex9927.htm EX-99.2 Exhibit 99.2 31 March 2022 Proposal for a restructuring plan pursuant to section 11c of the Danish Insolvency Act Orphazyme A/S in restructuring On 11 March 2022, at 7:00 CET, restructuring proceedings were commenced against Orphazyme A/S, Ole Maaløes Vej 3, 2200 Copenhagen N, Denmark, CVR no. 32266355. Particulars Restructuring administrator Restructuring account |
|
| March 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 29, 2022 |
Updated Financial Calendar for 2022 EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S in restructuring Company announcement No. 14/2022 Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Updated Financial Calendar for 2022 Copenhagen, Denmark, March 29, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, ann |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 22, 2022 |
Exhibit 99.1 Orphazyme A/S Company announcement No. 13/2022 Inside information Ole Maal?es Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme announces withdrawal of European Marketing Authorisation Application for arimoclomol for the treatment of Niemann-Pick disease type C ? Decision to withdraw the European Marketing Authorisation Application comes ahead o |
|
| March 22, 2022 |
Orphazyme A/S has filed for voluntary delisting of ADSs Exhibit 99.1 Orphazyme A/S Company announcement No. 12/2022 Ole Maal?es Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme A/S has filed for voluntary delisting of ADSs Copenhagen, Denmark, March 21, 2022 ? Orphazyme A/S (ORPHA.CO; ORPH) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company, announces that following the decision to voluntaril |
|
| March 21, 2022 |
As filed with the Securities and Exchange Commission on March 21, 2022 As filed with the Securities and Exchange Commission on March 21, 2022 Registration No. |
|
| March 21, 2022 |
As filed with the Securities and Exchange Commission on March 21, 2022 As filed with the Securities and Exchange Commission on March 21, 2022 Registration No. |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-39545 Orphazyme A/S The Nasdaq Global Select Market (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) Ole Maal? |
|
| March 21, 2022 |
As filed with the Securities and Exchange Commission on March 21, 2022 As filed with the Securities and Exchange Commission on March 21, 2022 Registration No. |
|
| March 18, 2022 |
Notice of in-court restructuring proceedings of Orphazyme A/S EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Company announcement No. 11/2022 Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Notice of in-court restructuring proceedings of Orphazyme A/S Copenhagen, Denmark, March 18, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces t |
|
| March 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 10, 2022 |
Commencement of in-court restructuring of Orphazyme A/S EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Company announcement No. 10/2022 Inside information Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Commencement of in-court restructuring of Orphazyme A/S • Will institute a reduction of approximately 50% of current work force • Intends to delist American Depositary Shares from Nasdaq US Copen |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 3, 2022 |
Updated Financial Calender for 2022 EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Company announcement No. 09/2022 Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Updated Financial Calender for 2022 Copenhagen, Denmark, March 3, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, today announced an update to the Finan |
|
| February 28, 2022 |
Anders Vadsholt takes over as CEO of Orphazyme EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Company announcement No. 08/2022 Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Anders Vadsholt takes over as CEO of Orphazyme Copenhagen, Denmark, February 28, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, today announces that CF |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive off |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive off |
|
| February 24, 2022 |
Orphazyme announces update on regulatory review of arimoclomol in the European Union EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Company announcement No. 07/2022 Inside information Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme announces update on regulatory review of arimoclomol in the European Union Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stag |
|
| February 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive off |
|
| February 18, 2022 |
EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Company announcement No. 06/2022 Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering Program Copenhagen, Denmark, February 18, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “ |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive off |
|
| February 15, 2022 |
Resolutions passed at the Extraordinary General Meeting EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Company announcement No. 05/2022 Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Resolutions passed at the Extraordinary General Meeting Copenhagen, Denmark, February 15, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the |
|
| February 14, 2022 |
Amendment of proposals put forward at the Extraordinary General Meeting EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Company announcement No. 04/2022 Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Amendment of proposals put forward at the Extraordinary General Meeting Copenhagen, Denmark, February 14, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive off |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive off |
|
| February 11, 2022 |
EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Investor news No. 02/2022 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States • Orphazyme has made progress towards resubmission of the NDA for arimoclomol to |
|
| February 3, 2022 |
ORPH / Orphazyme A/S / LSP V Cooperatieve U.A. - SC 13G/A Passive Investment SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Orphazyme A/S (Name of Issuer) Ordinary Shares (Title of Class of Securities) 687305102 (C |
|
| January 31, 2022 |
Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO Exhibit 99.1 Orphazyme A/S Company announcement No. 03/2022 Inside information Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Changes to the Executive Management of Orphazyme ? Anders Vadsholt to be appointed CEO Copenhagen, Denmark, January 31, 2022 ? Orphazyme A/S (ORPHA.CO; ORPH) (?Orphazyme? or the ?Company?), a late-stage biopharmaceutical company p |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive offi |
|
| January 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive offi |
|
| January 25, 2022 |
Appendix 1: Candidate for the Board of Directors Exhibit 99.3 Appendix 1: Candidate for the Board of Directors *Listed companies Andrew Mercieca New Board candidate Born in: London, UK Nationality: UK Special competences Andrew Mercieca has extensive experience in International Finance and across Life Science and Technology sectors in corporate, private and non-profit organisations. Andrew Mercieca has an exceptional track record of driving busi |
|
| January 25, 2022 |
Notice to convene Extraordinary General Meeting EX-99.1 2 orph-ex9917.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Company announcement No. 02/2022 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Notice to convene Extraordinary General Meeting Copenhagen, Denmark, January 24, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein respon |
|
| January 25, 2022 |
To the shareholders of Orphazyme A/S EX-99.2 3 orph-ex9926.htm EX-99.2 Exhibit 99.2 To the shareholders of Orphazyme A/S The Board of Directors hereby convenes an Extraordinary General Meeting of Orphazyme A/S, CVR no. 32 26 63 55 (the “Company”), to be held on Tuesday, February 15, 2022 at 5:00 PM (CET), at the Company’s address Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark. In order to continuously provide the Company with the n |
|
| January 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2022 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive offi |
|
| January 19, 2022 |
Orphazyme updates 2021 financial outlook EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Company announcement Orphazyme A/S No. 01/2022 Inside information Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme updates 2021 financial outlook • Net revenue range narrowed to DKK 35 – 37 million • Operating expenses lowered to DKK 665 – 675 million, due to strict cost management • Cash position as |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive off |
|
| December 9, 2021 |
Orphazyme announces changes to the Board of Directors EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Company announcement No. 27/2021 Ole Maaløes Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme announces changes to the Board of Directors Copenhagen – December 9, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces changes to the Board of |
|
| November 4, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-260283 PROSPECTUS SUPPLEMENT (To Prospectus dated October 22, 2021) Up to $50,000,000 Orphazyme A/S Ordinary Shares (including Ordinary Shares represented by American Depositary Shares) We have entered into a sales agreement with Cowen and Company, LLC, or Cowen, relating to American Depositary Shares, or ADSs, representing or |
|
| November 4, 2021 |
Sales Agreement, dated November 4, 2021, between Orphazyme A/S and Cowen and Company, LLC EX-1.1 2 d230045dex11.htm EX-1.1 Exhibit 1.1 ORPHAZYME A/S $50,000,000 AMERICAN DEPOSITARY SHARES EACH REPRESENTING ONE ORDINARY SHARE SALES AGREEMENT November 4, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Orphazyme A/S, a public limited liability company (Aktieselskab) organized and existing under the laws of the Kingdom of Denmark (the “Company”), c |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission file number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of Principal Executive Off |
|
| November 1, 2021 |
Exhibit 99.1 Orphazyme A/S Company announcement No. 24/2021 Inside information Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme provides regulatory update following Type A meeting with FDA on arimoclomol in Niemann-Pick disease type C ? Progress made in understanding potential resolution of topics outlined in Complete Response Letter, including n |
|
| November 1, 2021 |
6-K 1 orph-6k20211101.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant’s name into English) Ole Maaløes Vej 3, DK-2200 Copenhagen N Denmark (Addr |
|
| October 20, 2021 |
October 20, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tyler Howes Re: Orphazyme A/S (the ?Company?) Registration Statement on Form F-3 Filed: October 15, 2021 File No. 333-260283 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Se |
|
| October 15, 2021 |
As filed with the Securities and Exchange Commission on October 15, 2021. Table of Contents As filed with the Securities and Exchange Commission on October 15, 2021. |
|
| October 7, 2021 |
Modified long-term share-based incentive program for 2021 Exhibit 99.1 Orphazyme A/S Company announcement No. 23/2021 Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Modified long-term share-based incentive program for 2021 Copenhagen, Denmark, October 7, 2021 ? Orphazyme A/S (ORPHA.CO (DK); ORPH (US)), a late-stage biopharmaceutical company, has today introduced a modified long-term incentive program for 2021 ( |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive offi |
|
| October 5, 2021 |
Orphazyme provides regulatory and financial updates Exhibit 99.1 Orphazyme A/S Company announcement No. 22/2021 Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme provides regulatory and financial updates Copenhagen ? October 5, 2021 ? Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announces regulatory updates for its investigational drug candidate, arimoclomol, for wh |
|
| October 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive offi |
|
| August 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive offic |
|
| August 31, 2021 |
Interim Report First Half 2021 Exhibit 99.1 Company announcement No. 21/2021 Orphazyme A/S Ole Maal?es Vej 3 DK-2200 Copenhagen N CVR No.: 32266355 Interim Report First Half 2021 Copenhagen, Denmark, August 31, 2021 ? Orphazyme A/S (ORPHA.CO; ORPH) (?the Company?), a late-stage biopharmaceutical company, today announces its Interim Report First Half 2021 for the period January 1 ? June 30, 2021. ?We remain steadfast in our beli |
|
| June 28, 2021 |
Exhibit 99.1 Orphazyme A/S Company announcement No. 20/2021 Inside information Ole Maal?es Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC -Significant headcount reduction of global workforce to free resources- -Changes to the Board of Directors- -Outlook for 202 |
|
| June 28, 2021 |
Exhibit 99.2 Orphazyme A/S Company announcement No. 21/2021 Ole Maal?es Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme presents 36-month data supporting durable response to arimoclomol during Parseghian Scientific Conference for NPC Research Copenhagen ? June 28, 2021 ? Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announce |
|
| June 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| June 21, 2021 |
Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C Exhibit 99.1 Company announcement Orphazyme A/S No. 16/2021 Inside information Ole Maal?es Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C Copenhagen ? June 18, 2021 ? Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein re |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| June 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| June 11, 2021 |
EX-99.1 2 orph-ex9916.htm EX-99.1 Exhibit 99.1 Orphazyme A/S Company announcement No. 15/2021 Company Registration No. 32266355 Copenhagen – June 11, 2021 - Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of rare diseases, today announced that American Depositary Shares (ADSs) representing its ordinary shares on Na |
|
| May 7, 2021 |
Exhibit 99.1 Orphazyme A/S Company announcement No. 14/2021 Inside information Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme announces topline data from pivotal trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS) ?Pivotal trial did not meet primary and secondary endpoints evaluating impact on function and survival ?Orphazyme remains fo |
|
| May 7, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office) |
|
| April 30, 2021 |
Orphazyme A/S – Share-based Incentive Program for the Board of Directors for 2021 Exhibit 10.2 Template | [date] 2021 Orphazyme A/S ? Share-based incentive program for the Board of Directors for 2021 General Terms and Conditions Page: 2 of 7 Contents 1 Introduction 3 2 Grant of Restricted Share Units 3 3 Vesting of Restricted Share Units 3 4 Exercise of Restricted Share Units 4 5 Lapse of Restricted Share Units 4 6 Cash settlement 4 7 Claw back 4 8 Adjustments in case of change |
|
| April 30, 2021 |
As filed with the Securities and Exchange Commission on April 30, 2021 Registration No. |
|
| April 30, 2021 |
Orphazyme A/S – Long-Term Incentive Program Exhibit 10.1 19 April 2021 | U.S. participants Orphazyme A/S ? Long-Term Incentive Programme General Terms and Conditions for Restricted Share Units and Performance Share Units Page: 2 of 14 Contents 1 Introduction 3 2 Restricted Share Units (RSUs) 4 3 Performance Share Units (PSUs) 6 4 Cash settlement 9 5 Claw back 9 6 Adjustments in case of changes to the Company?s capital structure 9 7 Takeover |
|
| April 30, 2021 |
Articles of Association of Orphazyme A/S, as currently in effect Exhibit 4.1 Articles of Association Orphazyme A/S, CVR no. 32 26 63 55 Page: 2 of 9 1 Name and objects 1.1 The Company?s name is Orphazyme A/S. 1.2 The Company?s objects are research, development, production, marketing, sales and/or licensing of medicinal products for treatment of various disorders, including lysosomal storage diseases (LSD), neuromuscular disorders and other related diseases, as |
|
| April 22, 2021 |
New long-term share-based incentive program Exhibit 99.1 Company announcement Orphazyme A/S No. 13/2021 Ole Maal?es Vej 3, DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 New long-term share-based incentive program Copenhagen, Denmark, April 22, 2021 ? Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of neurodegenerative rar |
|
| April 22, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of April 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 29, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 29, 2021 |
Exhibit 99.1 Orphazyme Announces Topline Results from Pivotal Trial of Arimoclomol for Inclusion Body Myositis (IBM) Copenhagen – March 29, 2021 – Orphazyme A/S [ORPHA.CO (DK); ORPH (US)], a late-stage biopharmaceutical company pioneering the heat shock protein response for the treatment of neurodegenerative rare diseases, today announced its phase 2/3 trial evaluating arimoclomol for the treatmen |
|
| March 26, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 26, 2021 |
EX-3.1 2 orph-ex318.htm EX-3.1 Exhibit 3.1 Articles of Association Orphazyme A/S, CVR no. 32 26 63 55 Page: 2 of 9 1 Name and objects 1.1 The Company’s name is Orphazyme A/S. 1.2 The Company’s objects are research, development, production, marketing, sales and/or licensing of medicinal products for treatment of various disorders, including lysosomal storage diseases (LSD), neuromuscular disorders |
|
| March 26, 2021 |
Resolutions passed at the Annual General Meeting Exhibit 99.1 Company announcement Orphazyme A/S No. 08/2021 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Resolutions passed at the Annual General Meeting Copenhagen, Denmark, March 25, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegene |
|
| March 26, 2021 |
Articles of Association for Orphazyme A/S EX-99.2 4 orph-ex9926.htm EX-99.2 Exhibit 99.2 Company announcement Orphazyme A/S No. 10/2021 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Articles of Association for Orphazyme A/S Copenhagen, Denmark, March 25, 2021 – Orphazyme A/S (ORPHA.CO; ORPH) (“the Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for t |
|
| March 3, 2021 |
Notice to convene Annual General Meeting Exhibit 99.1 Company announcement Orphazyme A/S No. 07/2021 Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Notice to convene Annual General Meeting Copenhagen, Denmark, March 3, 2021 ? Orphazyme A/S (ORPHA.CO; ORPH) (the ?Company?), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative or |
|
| March 3, 2021 |
Appendix 1: Candidates for the Board of Directors Exhibit 99.3 Appendix 1: Candidates for the Board of Directors *Listed companies Georges Gemayel Chairman Member since: 2012 (Chairman since 2014) Born in: 1960 Nationality: American Committees: Nomination Committee (Chairman) Special competences Dr. Gemayel’s qualifications to sit on the Board of Directors include his significant management and executive experience in the global pharmaceutical in |
|
| March 3, 2021 |
To the shareholders of Orphazyme A/S EX-99.2 3 orph-ex9928.htm EX-99.2 Exhibit 99.2 To the shareholders of Orphazyme A/S The Board of Directors hereby convenes the Annual General Meeting of Orphazyme A/S, CVR no. 32 26 63 55 (the “Company”), to be held on Thursday, March 25, 2021 at 5:00 PM (CET), at the Company’s address Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark. In order to protect the health and safety of all, reduce the ri |
|
| March 3, 2021 |
Exhibit 99.4 Remuneration Policy Orphazyme A/S 1 Introduction 1.1 The Board of Directors of Orphazyme A/S, CVR no. 32 26 63 55 (?Orphazyme? or the ?Company?) has adopted this remuneration policy (the ?Remuneration Policy?) which describes the principles for payment of remuneration to the Board of Directors and the Executive Management in accordance with Sections 139 and 139(a) of the Danish Compan |
|
| March 3, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 2, 2021 |
Exhibit 12.2 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Anders Fink Vadsholt, certify that: 1. I have reviewed this annual report on Form 20-F of Orphazyme A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state |
|
| March 2, 2021 |
Exhibit 99.3 ANNUAL REPORT 2020 Advancing Lleyton Coombes Lleyton is 14 years old and suffers from treatment in Niemann-Pick disease Type C (NPC). Here he is pictured on set of award-win- ning Niemann-Pick UK (NPUK) short film “Go Make Memories” (2019). Lleyton was the only live-action actor featured in neurodegenerative the production, with his story directly in- spiring the film along with many |
|
| March 2, 2021 |
Exhibit 2.2 =============================================================== ORPHAZYME A/S AND THE BANK OF NEW YORK MELLON As Depositary AND OWNERS AND HOLDERS OF AMERICAN DEPOSITARY SHARES Deposit Agreement September 28, 2020 =============================================================== 7902075v.7 TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 1 SECTION 1.1. American Depositary Shares. 1 SECTION 1.2. |
|
| March 2, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| March 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 2, 2021 |
Consent of EY Godkendt Revisionspartnerselskab Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-249407) pertaining to the Orphazyme A/S – Long-Term Incentive Program (the “LTIP”) and Orphazyme A/S – Share-based Incentive Program for the Board of Directors (the “Board Incentive Program”) of Orphazyme A/S of our report dated March 2, |
|
| March 2, 2021 |
Articles of Association of Orphazyme A/S, as amended February 25, 2021 Exhibit 1.1 Articles of Association Orphazyme A/S, CVR no. 32 26 63 55 Page: 2 of 8 1 Name and objects 1.1 The Company’s name is Orphazyme A/S. 1.2 The Company’s objects are research, development, production, marketing, sales and/or licensing of medicinal products for treatment of various disorders, including lysosomal storage diseases (LSD), neuromuscular disorders and other related diseases, as |
|
| March 2, 2021 |
Description of Share Capital and Articles of Association Exhibit 2.1 DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION Securities registered under Section 12(b) of the Securities Exchange Act of 1934 (the ?Exchange Act?): Title of each class Trading Symbol(s) Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, nominal value DKK 1 per share Ordinary shares, nominal value DKK 1 per share* ORPH |
|
| March 2, 2021 |
Exhibit 99.1 Company announcement Orphazyme A/S No. 06/2021 Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme reports business highlights and financial results in Annual Report 2020 -Advanced arimoclomol in 4 rare disease indications; announced global brand name of arimoclomol (MIPLYFFATM1); PDUFA date of June 17, 2021 for NPC; MAA under review wi |
|
| March 2, 2021 |
Annual Report 2020 March 2, 2021 Intended for investor audiences only. Exhibit 99.2 Important notice: Forward-looking statements This company announcement may contain certain forward-looking statements, including in respect of the anticipated commercialization of arimoclomol. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of |
|
| March 2, 2021 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended December 31, 2020 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “E |
|
| March 2, 2021 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended December 31, 2020 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “E |
|
| March 2, 2021 |
Exhibit 12.1 CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Anders Fink Vadsholt, certify that: 1. I have reviewed this annual report on Form 20-F of Orphazyme A/S; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state |
|
| March 1, 2021 |
Orphazyme appoints Christophe Bourdon as Chief Executive Officer Exhibit 99.1 Company announcement No. 05/2021 Inside information Orphazyme A/S Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme appoints Christophe Bourdon as Chief Executive Officer Copenhagen, Denmark, March 1, 2021 ? Orphazyme A/S (ORPHA.CO; ORPH) (?Orphazyme?), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response |
|
| March 1, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive office |
|
| February 26, 2021 |
EXHIBIT 99.1 Company announcement Orphazyme A/S No. 04/2021 Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Capital increase of 80,553 shares (equivalent to approximately 0.23% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KUMCRI and directed issuance of new shares Copenhagen, Denmark, February 25, 2021 ? Orphazyme A/ |
|
| February 26, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of February 2021 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive off |
|
| February 26, 2021 |
Amended Articles of Association dated February 25, 2021 Exhibit 3.1 Articles of Association Orphazyme A/S, CVR no. 32 26 63 55 2 of 8 1 Name and objects 1.1 The Company?s name is Orphazyme A/S. 1.2 The Company?s objects are research, development, production, marketing, sales and/or licensing of medicinal products for treatment of various disorders, including lysosomal storage diseases (LSD), neuromuscular disorders and other related diseases, as well a |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Orphazyme A/S (Name of Issuer) Ordinary Shares, DKK 1 nominal value per share (Title of Class of Securities) 687305102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Orphazyme A/S (Name of Issuer) Ordinary Shares (Title of Class of Securities) 687305102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 9, 2021 |
Exhibit 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| February 8, 2021 |
EX-99 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| February 8, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Orphazyme A/S (Name of Issuer) Ordinary Shares (Title of Class of Securities) 687305102 (CUSIP Numbe |
|
| December 28, 2020 |
Orphazyme provides regulatory update on arimoclomol for NPC Exhibit 99.1 Company announcement No. 73/2020 Inside Information Orphazyme A/S Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme provides regulatory update on arimoclomol for NPC Copenhagen, Denmark – December 27, 2020 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatm |
|
| December 28, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2020 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant’s name into English) Ole Maaløes Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive off |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2020 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive off |
|
| December 10, 2020 |
Exhibit 99.1 Orphazyme A/S Company announcement No. 72/2020 Inside information Ole Maal?es Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Kim Stratton, CEO, resigns from Orphazyme Copenhagen, Denmark, December 10, 2020 ? Orphazyme A/S (ORPHA.CO) (?Orphazyme?), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neur |
|
| November 9, 2020 |
Exhibit 99.1 Company announcement Orphazyme A/S No. 70/2020 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme submits European Marketing Authorisation Application for arimoclomol for treatment of Niemann-Pick disease Type C • Follows U.S. Food and Drug Administration (FDA) acceptance of New Drug Application (NDA) with Priority Review in September |
|
| November 9, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2020 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant’s name into English) Ole Maaløes Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive off |
|
| October 23, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2020 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant?s name into English) Ole Maal?es Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive offi |
|
| October 23, 2020 |
Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020 Exhibit 99.1 Company announcement Orphazyme A/S No. 67/2020 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme accelerates arimoclomol pre-launch activities and updates financial outlook for 2020 Copenhagen, Denmark, October 23, 2020 – Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein (HSP) response |
|
| October 9, 2020 |
Exhibit 10.1 Orphazyme A/S – Long-Term Incentive Programme General Terms and Conditions Page 2 Contents 1 Introduction 3 2 Matching Shares 4 3 Performance Shares 5 4 Ownership of Investment Shares 6 5 Continued Employment or Good Leaver 6 6 Receipt of Matching Shares and Performance Shares 7 7 Cash settlement 8 8 Claw back 8 9 Adjustments in case of changes to the Company’s capital structure 9 10 |
|
| October 9, 2020 |
Orphazyme A/S – Share-based Incentive Program for the Board of Directors Exhibit 10.2 Orphazyme A/S – Share-based incentive program for the Board of Directors General Terms and Conditions Page 2 Contents 1 Introduction 3 2 Grant of Restricted Share Units 3 3 Vesting of Restricted Share Units 4 4 Exercise of Restricted Share Units 4 5 Lapse of Restricted Share Units 4 6 Cash settlement 5 7 Claw back 5 8 Adjustments in case of changes to the Company’s capital structure 5 |
|
| October 9, 2020 |
Articles of Association of Orphazyme A/S, as currently in effect Exhibit 4.1 Articles of Association Orphazyme A/S, CVR no. 32 26 63 55 002 page 2 of 8 1 Name and objects 1.1 The Company’s name is Orphazyme A/S. 1.2 The Company’s objects are research, development, production, marketing, sales and/or licensing of medicinal products for treatment of various disorders, including lysosomal storage diseases (LSD), neuromuscular disorders and other related diseases, |
|
| October 9, 2020 |
As filed with the Securities and Exchange Commission on October 9, 2020 Registration No. |
|
| October 2, 2020 |
Exhibit 99.4 Company announcement Orphazyme A/S No. 59/2020 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe ▪ Orphazyme A/S has today registered a capital increase of new o |
|
| October 2, 2020 |
Exhibit 99.2 Company announcement Orphazyme A/S No. 57/2020 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme publishes a prospectus regarding listing of 7,616,146 new ordinary shares on Nasdaq Copenhagen in connection with a global offering ▪ Orphazyme has today published a listing prospectus which has been approved by the Danish Financial Superv |
|
| October 2, 2020 |
Exhibit 99.1 Company announcement Orphazyme A/S No. 55/2020 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe ▪ As announced on September 21, 2020, Orphazyme commenced an ini |
|
| October 2, 2020 |
Articles of Association of the Registrant Exhibit 3.1 Articles of Association Orphazyme A/S, CVR no. 32 26 63 55 002 page 2 of 8 1 Name and objects 1.1 The Company’s name is Orphazyme A/S. 1.2 The Company’s objects are research, development, production, marketing, sales and/or licensing of medicinal products for treatment of various disorders, including lysosomal storage diseases (LSD), neuromuscular disorders and other related diseases, |
|
| October 2, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October 2020 Commission File Number: 001-39545 Orphazyme A/S (Translation of registrant’s name into English) Ole Maaløes Vej 3, DK-2200 Copenhagen N Denmark (Address of principal executive offi |
|
| October 2, 2020 |
Exhibit 99.3 Company announcement Orphazyme A/S No. 58/2020 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 Orphazyme files final prospectus in connection with a global offering, consisting of initial public offering of American Despositary Shares in the United States and concurrent private placement of ordinary shares in Europe ▪ Orphazyme has filed a fi |
|
| September 29, 2020 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) File Number 333-248607 P R O S P E C T U S 7,616,146 Ordinary Shares (including Ordinary Shares in the form of American Depositary Shares) Orphazyme A/S $11. |
|
| September 28, 2020 |
F-1/A Table of Contents As filed with the Securities and Exchange Commission on September 28, 2020. |
|
| September 28, 2020 |
CORRESP Josh Kaufman (212) 479-6495 [email protected] VIA EDGAR September 28, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. Alan Campbell Ms. Christine Westbrook Mr. David Burton Ms. Mary Mast Re: Orphazyme A/S Amendment No. 4 to Registration Statement on Form F-1 Filed S |
|
| September 25, 2020 |
FWP Issuer Free Writing Prospectus dated September 25, 2020 Filed Pursuant to Rule 433 under the Securities Act of 1933 Relating to the Preliminary Prospectus dated September 23, 2020 Registration Statement No. |
|
| September 25, 2020 |
FWP Issuer Free Writing Prospectus dated September 25, 2020 Filed Pursuant to Rule 433 under the Securities Act of 1933 Relating to the Preliminary Prospectus dated September 25, 2020 Registration Statement No. |
|
| September 25, 2020 |
F-1/A Table of Contents As filed with the Securities and Exchange Commission on September 25, 2020. |
|
| September 25, 2020 |
September 25, 2020 U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. Alan Campbell Ms. Christine Westbrook Mr. David Burton Ms. Mary Mast Re: Orphazyme A/S Registration Statement on Form F-1, as amended File No. 333-248607 Ladies and Gentlemen: In connection with the above-referenced Re |
|
| September 25, 2020 |
CORRESP Ole Maaløes Vej 3, DK-2200 Copenhagen N Denmark VIA EDGAR September 25, 2020 U. |
|
| September 24, 2020 |
F-1/A As filed with the Securities and Exchange Commission on September 24, 2020. Registration Statement No. 333-248607 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Orphazyme A/S (Exact name of Registrant as specified in its charter) The Kingdom of Denmark 2834 Not applicable (State or ot |
|
| September 24, 2020 |
CORRESP Josh Kaufman (212) 479-6495 [email protected] VIA EDGAR September 24, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. Alan Campbell Ms. Christine Westbrook Mr. David Burton Ms. Mary Mast Re: Orphazyme A/S Amendment No. 2 to Registration Statement on Form F-1 Filed S |
|
| September 23, 2020 |
F-1/A Table of Contents As filed with the Securities and Exchange Commission on September 23, 2020. |
|
| September 23, 2020 |
Josh Kaufman (212) 479-6495 [email protected] VIA EDGAR September 23, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. Alan Campbell Ms. Christine Westbrook Mr. David Burton Ms. Mary Mast Re: Orphazyme A/S Amendment No. 1 to Registration Statement on Form F-1 Filed September |
|
| September 23, 2020 |
FWP Issuer Free Writing Prospectus dated September 23, 2020 Filed Pursuant to Rule 433 under the Securities Act of 1933 Relating to the Preliminary Prospectus dated September 21, 2020 Registration Statement No. |
|
| September 22, 2020 |
Company Acceleration Request Ole Maaløes Vej 3, DK-2200 Copenhagen N Denmark VIA EDGAR September 22, 2020 U. |
|
| September 22, 2020 |
September 22, 2020 U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. Alan Campbell Ms. Christine Westbrook Mr. David Burton Ms. Mary Mast Re: Orphazyme A/S Registration Statement on Form F-1, as amended File No. 333-248607 Ladies and Gentlemen: In connection with the above-referenced Re |
|
| September 22, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934 Orphazyme A/S (Exact Name of Registrant as Specified in its Charter) Denmark N/A (State or Other Jurisdiction of Incorporation or Organization) (I. |
|
| September 21, 2020 |
Power of Attorney (included on signature page to this registration statement) F-1/A Table of Contents As filed with the Securities and Exchange Commission on September 21, 2020. |
|
| September 21, 2020 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 ORPHAZYME A/S (a Danish public limited liability company) [•] Ordinary Shares (nominal value DKK 1 per share) and [•] American Depositary Shares each Representing One Ordinary Share UNDERWRITING AGREEMENT Dated: [•], 2020 ORPHAZYME A/S (a public limited liability company (Aktieselskab) organized and existing under the laws of the Kingdom of Denmark) [•] Ordinary Shares (nominal |
|
| September 21, 2020 |
Form of Articles of Association of Orphazyme A/S to be effective after the initial public offering EX-3.2 Exhibit 3.2 Articles of Association Orphazyme A/S, CVR no. 32 26 63 55 002 Page: 2 of 8 1 Name and objects 1.1 The Company’s name is Orphazyme A/S. 1.2 The Company’s objects are research, development, production, marketing, sales and/or licensing of medicinal products for treatment of various disorders, including lysosomal storage diseases (LSD), neuromuscular disorders and other related di |
|
| September 21, 2020 |
Articles of Association of Orphazyme A/S, as currently in effect EX-3.1 Exhibit 3.1 Articles of Association Orphazyme A/S, CVR no. 32 26 63 55 002 Page: 2 of 8 1 Name and objects 1.1 The Company’s name is Orphazyme A/S. 1.2 The Company’s objects are research, development, production, marketing, sales and/or licensing of medicinal products for treatment of various disorders, including lysosomal storage diseases (LSD), neuromuscular disorders and other related di |
|
| September 4, 2020 |
Consent of Director Nominee Carrolee Barlow Exhibit 99.1 CONSENT OF PERSON TO BE NAMED DIRECTOR As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned consents to being named in the Registration Statement on Form F-1 (together with any amendments or supplements thereto, the “Registration Statement”) of Orphazyme A/S, a public limited liability company (Aktieselskab) organized and existing under the laws of Den |
|
| September 4, 2020 |
Exhibit 10.2 [*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. UNIVERSITY OF MIAMI EXCLUSIVE LICENSE AGREEMENT This Exclusive License Agreement (this ?Agreement?) is entered into and made effective as of the last dated signature below (the ?Effective Da |
|
| September 4, 2020 |
F-1 Table of Contents As filed with the Securities and Exchange Commission on September 4, 2020. |
|
| September 4, 2020 |
CORRESP Josh Kaufman (212) 479-6495 [email protected] VIA EDGAR September 4, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. David Burton Ms. Mary Mast Mr. Alan Campbell Ms. Christine Westbrook Re: Orphazyme A/S Amendment No. 1 to Draft Registration Statement on Form F-1 Su |
|
| September 4, 2020 |
Asset Purchase Agreement, dated May 13, 2011, between Orphazyme A/S and CytRx Corporation Exhibit 10.1 [*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. ASSET PURCHASE AGREEMENT by and between CytRx Corporation, as Seller, and Orphazyme ApS, as Buyer May 13, 2011 ASSET PURCHASE AGREEMENT This Asset Purchase Agreement (this ?Agreement?) is ma |
|
| September 4, 2020 |
Exhibit 10.3 Execution Version [*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENSE AGREEMENT dated October 31 2017 between Orphazyme A/S and KU Center for Technology Commercialization, Inc. and University of Kansas and Kansas Life Sciences Develop |
|
| September 4, 2020 |
Subsidiaries of the registrant Exhibit 21.1 Subsidiaries Name of Subsidiary State or Other Jurisdiction of Incorporation Orphazyme US, Inc. Delaware Orphazyme Schweiz GmbH Switzerland |
|
| September 4, 2020 |
Exhibit 10.4 EXECUTION VERSION AGREEMENT FOR THE PROVISION OF A LOAN FACILITY OF UP TO ?18,000,000 Dated 27th August 2019 Between KREOS CAPITAL VI (UK) LIMITED, a company incorporated in England and Wales under registration number 11535385 whose registered office is at Amf Building, 25 Old Burlington Street, London W1S 3AN (the ?Lender?, which expression shall include its successors and assigns); |
|
| August 5, 2020 |
AGREEMENT FOR THE PROVISION OF A LOAN FACILITY OF UP TO €18,000,000 Dated 27th August 2019 Exhibit 10.4 EXECUTION VERSION AGREEMENT FOR THE PROVISION OF A LOAN FACILITY OF UP TO €18,000,000 Dated 27th August 2019 Between KREOS CAPITAL VI (UK) LIMITED, a company incorporated in England and Wales under registration number 11535385 whose registered office is at Amf Building, 25 Old Burlington Street, London W1S 3AN (the "Lender", which expression shall include its successors and assigns); |
|
| August 5, 2020 |
Josh Kaufman (212) 479-6495 [email protected] Via EDGAR August 5, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Mail Stop 4546 Washington, D.C. 20549 Attn: Mr. David Burton Ms. Mary Mast Mr. Alan Campbell Ms. Christine Westbrook Re: Orphazyme A/S Draft Registration Statement on Form F-1 Submitted June 30, 2020 CIK No. |
|
| August 5, 2020 |
[*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
|
| August 5, 2020 |
As confidentially submitted to the Securities and Exchange Commission on August 5, 2020 as Amendment No. |
|
| June 30, 2020 |
EX-21 2 filename2.htm Exhibit 21.1 Subsidiaries Name of Subsidiary State or Other Jurisdiction of Incorporation Orphazyme US, Inc. Delaware Orphazyme Schweiz GmbH Switzerland |
|
| June 30, 2020 |
As confidentially submitted to the Securities and Exchange Commission on June 30, 2020. |
